Translational Relevance
PIK3CA and PTEN mutations are common in colorectal cancer (CRC), and potential markers of response to MEK inhibitors and anti-EGFR antibody therapy. This cohort study and integrated analysis with 17 previous reports defines the characteristics of PIK3CA and PTEN mutated CRCs. We show that PI3K pathway mutation is prominent in proximal colon cancers, with Author Manuscript Published OnlineFirst on April 30, 2013; DOI: 10.1158 /1078 INTRODUCTION PI3-kinase (PI3K) and PTEN are key positive and negative regulators of the PI3-kinase pathway, respectively, involved in cell growth, survival, proliferation, motility and glucose homeostasis (1) . Activating mutations in PIK3CA, the gene encoding the catalytic p110α subunit of class IA PI3Ks, occur in ~15% of human colorectal cancers (CRCs). The majority (~80%) of PIK3CA mutations cluster in two "hotspot" regions, the helical domain (exon 9) and the kinase domain (exon 20) (2) (3) (4) (5) . In addition, inactivating PTEN mutations or loss of protein expression is found in ~5% and ~30% of sporadic CRCs (6) (7) (8) .
PIK3CA and PTEN status are implicated as markers of CRC response to MEK inhibitors and anti-EGFR antibody therapy (cetuximab or panitumumab). Some but not all studies of anti-EGFR antibody treatment in metastatic CRC have reported resistance for tumors with PIK3CA mutation or PTEN loss (9) (10) (11) , and similar results have been obtained in preclinical studies of MEK inhibition for KRAS mutated CRC cell lines (12) . Conversely, KRAS mutation has been associated with resistance to single agent PI3K inhibitors (13), but such cell lines may respond to concomitant inhibition of the PI3K and MAPK pathways (14) . Based on these and other findings, drug combination studies of MAP2K and PI3K or mTOR inhibitors have been proposed tailored to tumor PI3K and MAPK pathway mutation status (15) .
Despite their clinical importance, data on the baseline relationships of molecular features and prognosis remain controversial. For PTEN, inactivating mutations have been demonstrated to be associated with microsatellite instability (MSI) status, occurring in ~20% of MSI-high (MSI-H) (16) (17) (18) and <5% microsatellite stable (MSS) tumors (19, 20) . However, associations with advanced tumor stage and poor outcome are less certain (11, (21) (22) (23) (24) . PIK3CA mutations have been reported to be more frequent in women (8, 25, 26) , proximal (26) , well-differentiated (5) and mucinous tumors (5) , but these findings have not been consistent (4, 8, 27, 28) . Some studies have reported significant co-occurrence of PIK3CA and KRAS mutations (5, 26, (28) (29) (30) (31) (32) , whereas others have failed to demonstrate this (8, 25) . Other, inconsistent data have been reported for PIK3CA mutation and MSI or CpG island methylator phenotype (CIMP) status (4, 8, 26, 28, 31, 32) . Poorer outcomes have been suggested for PIK3CA-mutated tumors for patients with early-stage resectable disease (27, 28) , but this was not replicated in a recent large series (32) .
Emerging data indicate that the conflicting PIK3CA association data may in part be explained by intrinsic differences between exon 9 and 20 mutated cancers. Two recent studies on stage I-IV CRCs have suggested that exon 20 mutations correlate more strongly with BRAF mutation, CIMP-high/-low (CIMP-H/-L) and MSI-H status (31, 32) , and one reported that exon 9 mutations may more closely associate with KRAS mutation (31, 32) . The latter has further been observed in a study on metastatic CRC (30) April 30, 2013; DOI: 10.1158 /1078 exonic mutant and wild-type tumors, rather than direct comparisons between exon 9 and 20 mutated cases required to substantiate such relationships.
The prognostic value of PIK3CA mutation may also vary by exon mutation status, with one study reporting an association of exon 20 but not exon 9 mutations with worse outcome in stage III tumors (33) . However, another large study of patients with stage I-IV CRC found no effect of either exon 9 or 20 mutations on survival; instead, a small proportion of tumors with concomitant exon 9 and 20 mutations were reported to show poor outcomes (32) . In addition, exonic location of PIK3CA mutation may influence response to anti-EGFR antibody therapy, with a recent analysis of multiple cohorts suggesting that mutations in PIK3CA exon 20 but not exon 9 are predictive of tumor resistance (34).
To comprehensively define the characteristics of PIK3CA and PTEN mutated CRC, we have analyzed 1,093 stage I-IV cancers for gene and exon mutation-specific relationships with patient clinicopathological and tumor molecular features including KRAS, BRAF, MSI and CIMP status.
Associations with prognosis were investigated for persons with resected stage II/III cancer. To refine results on PIK3CA exon 9 and 20 mutation-specific associations, our data were integrated with 17 published cohorts comprising a total of 5,590 CRC patients.
Research. April 30, 2013; DOI: 10.1158 /1078 Table 1 .
MATERIALS AND METHODS

Patients
Microsatellite instability analysis
H&E-stained tissue sections were reviewed, and for tumor samples areas with >60% neoplastic cells were macrodissected. DNA was extracted using standard protocols, and PCR-amplified for the Bethesda consensus panel of microsatellite markers (BAT25, BAT26, D2S123, D5S346, D17S250) using fluorescently-labeled primers (35) . Reaction products were analyzed on a April 30, 2013; DOI: 10.1158 /1078 3130xl Genetic Analyzer (Applied Biosystems). MSI-H was diagnosed if instability was evident at two or more markers.
Mutation detection
Mutation screening for PTEN (exons [3] [4] [5] [6] [7] [8] , PIK3CA (exons 9/20), KRAS (codons 12/13) and BRAF (codon 600) was performed by Sanger sequencing using the BigDye® Terminator v3.1 Ready Reaction Mix (Applied Biosystems; details available from authors). Sequencing reaction products were analyzed on a 3730xl DNA Analyzer (Applied Biosystems), and detected mutations confirmed by re-sequencing of tumor and matched normal DNA from new PCR product.
CIMP marker analysis
Tumor CIMP status was determined using MethyLight real-time PCR for the Weisenberger et al. five marker panel (IGF2, SOCS1, RUNX3, CACNA1G, NGN1) and the reference gene ALU (C-4) (36) . The percentage of methylated reference (PMR) was calculated for GENE:ALU ratio of template amount in a sample against GENE:ALU ratio of template amount in methylated reference DNA. Tumors with a PMR greater than 10 for three to five CIMP markers were classified as CIMP-H, those with one to two methylated markers as CIMP-L and zero methylated markers as CIMP-0.
Research. April 30, 2013; DOI: 10.1158 /1078 Loss of heterozygosity analysis LOH at the PTEN locus was determined from single nucleotide polymorphism (SNP) array data for tumor and matched normal samples (Human610-Quad BeadChip arrays, Illumina) using OncoSNP software (Isis Innovations, Oxford, UK) as described previously (37) . SNP call rates for normal samples were >98% and for tumor samples were >97%.
Statistical analyses
Statistical analyses were performed using the statistical computing software R (R Development Core Team, 2011). For univariate analyses, differences between groups were assessed using Fisher's exact test for categorical variables and Kruskal-Wallis test for continuous variables. Multivariate analyses for association between gene mutation and clinicopathological or molecular features were performed using logistic regression. Integrated multicohort analysis for PIK3CA exon mutation-specific associations was performed using the DerSimonian-Laird random effects pooling method (38) (rmeta R package version 2.16) and mixed effects logistic regression with the association of interest treated as fixed effect and the study as random effect.
Inter-study heterogeneity was assessed using Woolf's test. Changes in proportions of tumor MSI/CIMP/KRAS/BRAF genotypes according to PIK3CA exon 9 or 20 mutation status were estimated using mixed effects logistic regression and a three-stage hierarchical multinomial-Dirichlet model Author Manuscript Published OnlineFirst on April 30, 2013; DOI: 10.1158 /1078 II/III CRC were performed for 5-year disease-free survival (DFS). DFS was defined as time from surgery to the first confirmed relapse, with censoring done when a patient died or was alive without recurrence at last contact.
Survival curves were generated according to the method of Kaplan and Meier.
Univariate survival distributions were compared using the log-rank test, and multivariate analyses used Cox proportional hazards models. All statistical analyses were two-sided and considered significant if P<0.05. Author Manuscript Published OnlineFirst on April 30, 2013; DOI: 10.1158 /1078 Among 744 CRCs with complete mutation data for both PIK3CA and PTEN, 16.9% (n=126) of cases showed mutations in either PI3K pathway member. A subset of 1.2% (n=9) of tumors harbored mutations in both genes, perhaps suggesting synergy, although this was only borderline statistically significant (P=0.092).
RESULTS
PIK3CA and PTEN mutation prevalence and spectra
Clinicopathological and molecular associations of PIK3CA mutation
Clinicopathological and molecular correlates of PIK3CA mutation were evaluated overall and according to exonic location. Overall PIK3CA gene mutation was significantly associated with older age at diagnosis, proximal tumor site, mucinous histology and presence of KRAS mutation (P≤0.037 for all comparisons), but not with patient gender, tumor stage, differentiation, BRAF mutation, MSI or CIMP status (Table 1 ). In analyses stratified by MSI status, the relationships with older age, proximal tumor site and KRAS mutation remained significant for MSS cancers (P≤0.010 for all comparisons), while the relationship with mucinous histology was observed for MSI-H cancers only (P=0.004; Supplementary Table 4) .
While some of these associations were evident for both exon 9 and exon 20 mutations separately, others appeared to be exon-specific (Table 2 ).
Compared to PIK3CA wild-type status, mutation of either exon 9 or 20 alone was significantly associated with proximal tumor location (P≤0.002 for both comparisons). In contrast, mucinous histology was specific to exon 20
Research. April 30, 2013; DOI: 10.1158 /1078 mutated tumors when compared to both wild-type and exon 9 mutated tumors (P≤0.045 for both comparisons). The significant relationship with older age at diagnosis and KRAS mutation was observed for exon 9 but not exon 20 mutation as compared to wild-type (age: P=0.023 vs. P=0.139; KRAS:
P<0.001 vs. P=0.318), although the direct comparisons between exon 9 and 20 mutated cases did not reach statistical significance (age: P=0.810; KRAS: P=0.095). Common and differential relationships by exon mutation status remained apparent in analyses stratified by MSI status. In MSS cancers, exon 9 and 20 mutations were both associated with proximal tumor location (P≤0.024 for both comparisons), while associations with older age and KRAS mutation were significant only for exon 9 (age: P=0.014, KRAS: P<0.001). In MSI-H cancers, exon 9 mutation occurred with KRAS mutation (P=0.042), and exon 20 mutation with mucinous histology (P=0.009; Supplementary Table 5 ).
In multivariate logistic regression analysis to assess for independent relationships between PIK3CA mutation and clinicopathological or molecular features, proximal tumor location was significantly associated with overall PIK3CA gene mutation (P=0.002; Supplementary Table 6 ). For a model excluding CIMP status, which was only available for a limited subset of patients, KRAS mutation was further independently associated with overall PIK3CA gene mutation (P=0.034; Supplementary Table 6 ). In multivariate analyses by exonic site, a significant independent association with proximal location was observed for either exon 9 or exon 20 mutation compared to PIK3CA wild-type (P≤0.028 for both comparisons), while an independent relationship with KRAS mutation was observed only for exon 9 mutated Table 9 ).
Clinicopathological and molecular associations of PTEN mutation
In the 744 CRC patients evaluated for PTEN, presence of mutation was significantly associated with proximal tumor location, mucinous histology, 
PIK3CA or PTEN mutation and outcome in stage II and III CRC
For patients with resected stage II or III CRC, the influence of PI3K pathway mutation status on DFS was assessed using Cox proportional hazards analysis. Clinical follow-up information was available for 585 patients analyzed for PIK3CA mutation, and 381 patients analyzed for both PIK3CA
and PTEN mutation. The median duration of follow-up was 32 months for the former and 33 months for the latter patient group.
In both univariate and multivariate analyses adjusted for age at diagnosis, gender, tumor location, stage, differentiation, MSI status and adjuvant treatment ( April 30, 2013; DOI: 10.1158 /1078 Integrated analysis of PIK3CA exon 9 and 20 mutations for clinicopathological and molecular associations
To further refine our analysis of the clinicopathological and molecular associations of PIK3CA exon 9 or 20 mutated tumors, we identified previous publications reporting such details using the PubMed literature search engine Table 17 ). Tumors with mutations in both PIK3CA exons 9 and 20 were excluded. To maintain consistency for evaluation of KRAS and BRAF, mutation data were limited to KRAS codons 12 and 13 and the BRAF codon 600 (V600E). Odds ratios (ORs) for integrated studies were calculated for PIK3CA exon 9 or 20 mutation versus wild-type, and exon 20 versus exon 9 mutation using two alternative approaches, the DerSimonian-Laird random effects pooling method and mixed effects logistic regression.
In the integrated multi-cohort analysis using the DerSimonian-Laird approach ( Figure 1 ; Supplementary Table 18 ). Integrated multi-cohort analysis using the mixed effects logistic regression identified the same associations, and additionally provided suggestive evidence for an inverse association between exon 9 mutation and BRAF mutation and an underrepresentation of exon 20 mutations in stage III versus stage I/II tumors as compared to wild-type (Supplementary Figure 2) .
Analyses excluding data from this study reproduced these results, although in the direct comparison between exon 20 and exon 9 mutated cancers, the exon 20 mutation association with KRAS wild-type reached only borderline statistical significance (Supplementary Figure 3) .
Differential tumor MSI/CIMP/KRAS/BRAF genotypes according to
PIK3CA exon 9 or 20 mutation status
To further define the differential associations of PIK3CA exon 9 or 20 mutation with tumor location, MSI, CIMP, KRAS and BRAF mutation, combined analysis was performed for cohorts with available complete patient data to test for differences in proportions of tumor compound genotypes (n=1,318;
Research. April 30, 2013; DOI: 10.1158 /1078 this study, TCGA (39) and Whitehall et al. (31) Figure 4) .
Direct comparisons between PIK3CA exonic mutants did not reach statistical significance, although power to detect such differences was limited due to small sample sizes.
DISCUSSION
This study presents the first substantial survey of somatic PTEN mutations in sporadic CRC and is the most comprehensive analysis to date of PIK3CA exon mutation-specific associations with patient characteristics, tumor molecular features and outcome. Our findings demonstrate significant gene and exon mutation-specific differences in clinicopathological and molecular
Research. April 30, 2013; DOI: 10.1158 /1078 associations for PIK3CA and PTEN and clarify previous data on the prognostic value of these changes in resected stage II/III CRC. Consistent with previous studies, PIK3CA mutations in exon 9 or 20 were detected in 12% of sporadic CRCs with mutation of the former exon about twice as frequent as the latter (2) (3) (4) (5) . Approximately 0.3% of CRCs had two detected mutations as reported by others (2, 11, 26, 30, 32 April 30, 2013; DOI: 10.1158 /1078 PIK3CA gene mutation was significantly associated with older age at diagnosis, proximal tumor location, mucinous histology and presence of KRAS mutation, relationships which have been described in a number of reports (5, 26, (28) (29) (30) (31) (32) . However, when stratified by exonic location, significant differences were evident between PIK3CA exon 9 and 20 mutation in our cohort. Compared to both wild-type and exon 9 mutated tumors, the relationship with mucinous histology was specific to exon 20 mutation.
Somatic mutations in
Furthermore, the associations with older age at diagnosis and KRAS mutation appeared stronger for exon 9 mutated tumors, although the direct comparison to exon 20 mutated tumors did not reach statistical significance. A PIK3CA exon 9 mutation-specific association with KRAS mutation has been suggested by others, but a statistical difference as compared to exon 20 mutation was also not formally demonstrated in these reports (30) (31) (32) . In an analysis stratified by MSI status, the association between PIK3CA exon 9 mutation and KRAS mutation was observed for both MSS and MSI-H cases, but the association between PIK3CA exon 20 mutation and mucinous histology was evident for MSI-H cases only.
Given the limited power to demonstrate PIK3CA exon mutation-specific clinicopathological and molecular associations in our and previous studies, we tumors (15) . Optimization of the design of such clinical trials for CRC requires a detailed knowledge of the prevalence of these respective mutation genotypes. Here, we estimate that approximately 6.0% of sporadic CRCs are KRAS/PIK3CA and 1.5% BRAF/PIK3CA double-mutant (integrated analysis), and 1.5% are KRAS/PTEN, 1.9% BRAF/PTEN and 1.2% PIK3CA/PTEN double-mutant (this study). The low frequencies of these double-mutant cases underscore the need for collaborative international efforts to undertake such drug combination studies.
In our cohort, PIK3CA, PTEN or overall PI3K pathway mutation status were not associated with prognosis of resected stage II/III CRC, and similar results were obtained when analyzing PIK3CA exon 9 or 20 status separately.
Findings were similar when separating patients into groups who did and did not receive adjuvant chemotherapy. Our results for overall PIK3CA mutation contrast with some smaller previous studies reporting shorter RFS for PIK3CA-mutated stage II/III CRC (27) and inferior time to local failure for stage I-III rectal cancer (44) . However, in line with our findings a recent analysis of 1,170 stage I-III CRC patients did not find an association between PIK3CA mutation status and cancer-specific survival, either overall or for exon 9 or 20 alone, although adjuvant treatment details were not available (32) .
Taken together, the current evidence does not support a role for PIK3CA and/or PTEN mutation as a prognostic biomarker for CRC.
Potential caveats to our findings include that mutation screening was limited to PIK3CA mutation hotspots and certain PTEN exons. Although the Author Manuscript Published OnlineFirst on April 30, 2013; DOI: 10.1158 /1078 selected regions have been demonstrated to comprise the majority of mutations in CRC (www.sanger.ac.uk/genetics/CGP/cosmic), this may have impacted on the power to detect significant clinicopathological, molecular and outcome associations. Furthermore, loss of PTEN protein expression, observed in ~30% of CRCs (6) (7) (8) , is a documented alternative to mutation, and our study will therefore have underestimated the overall frequency of PTEN inactivation. Although no significant inter-study heterogeneity was observed in our integrated multi-cohort analysis for molecular variables, some heterogeneity was evident for patient gender.
In conclusion, our data suggest a model in which PIK3CA exon 20 and Research. mutation status. Estimates and 95% confidence intervals were calculated using a mixed effects logistic regression model; only the 8 most numerous tumor states were modeled, with the remaining states combined into an "other classes" category. This analysis pooled data from three data sources: this study, the TCGA (39) and Whitehall et al. (31) . 
